Evenamide

Evenamide (INNTooltip International Nonproprietary Name) (developmental code names NW-3509, NW-3509A)^[1] is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Na_v1.3, Na_v1.7, and Na_v1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.^[2][3][4][5] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.^[4] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.^[6]

Evenamide

Clinical data
Other names	NW-3509; NW-3509A
Routes of administration	oral
ATC code	None
Identifiers
IUPAC name 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
CAS Number	1092977-61-1 Y
PubChem CID	25105689
ChemSpider	44208827
UNII	ON5S6N53JS
CompTox Dashboard (EPA)	DTXSID101032897
Chemical and physical data
Formula	C16H26N2O2
Molar mass	278.396 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCOc1cccc(CCNCC(=O)N(C)C)c1
InChI InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3 Key:GRHBODILPPXVKN-UHFFFAOYSA-N

The drug was discovered by Newron Pharmaceuticals SpA, a pharmaceutical company located in Italy^[7]

Clinical studies

In a randomized study with treatment-resistant schizophrenia patients, evenamide was added to the treatment regimen, with the psychological assessors being blinded to whether evenamide was taken. 70% of the participants reported a significant lowering of their impairments; and in 25%, schizophrenia went in full remission. A full double-blind phase III study with treatment-resistant schizophrenia patients is in preparation as of January 2023.^[8]

The 4 week placebo trial of 2021 to evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide for people with chronic schizophrenia was selected to address patients who are receiving treatment at constant doses of one of the following atypical antipsychotics: aripiprazole, clozapine, quetiapine, olanzapine, paliperidone or risperidone.^[9][10]

See also

• List of investigational antipsychotics